GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

rosnilimab   Click here for help

GtoPdb Ligand ID: 14271

Synonyms: ANB-030 | ANB030
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rosnilimab (ANB-030; AnaptysBio) is a programmed cell death 1 (PD-1) monoclonal antibody that activates the PD-1 signaling pathway as a mechanism to suppress pathogenic T cell-mediated immune activation for the treatment of autoimmune disorders [1,3-4]. PD-1 agonist monoclonals are claimed in AnaptysBio patent US20220235132 [2]. Peptide sequences for 3.7C6 (APE12095) clones in this patent match the complementarity-determining region (CDR) sequences that form the antigen-binding site of rosnilimab, as annotated by IMGT.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Rosnilimab (ANB-030) was progressed to clinical evaluations to determine safety and efficacy for the treatment of the autoimmune conditions, alopecia areata, rheumatoid arthritis and ulcerative colitis. Due to lack of efficacy in mid-phase 2, AnaptysBio terminated development in ulcerative colitis (November 2025).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05205070 A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata Phase 2 Interventional AnaptysBio, Inc.
NCT06041269 A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) Phase 2 Interventional AnaptysBio, Inc.
NCT06127043 A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) Phase 2 Interventional AnaptysBio, Inc.